Literature DB >> 8267889

Rapid resolution of visual abnormalities with medical therapy alone in patients with large prolactinomas.

J C Mbanya1, A D Mendelow, P J Crawford, K Hall, J H Dewar, P Kendall-Taylor.   

Abstract

Large prolactin-secreting pituitary adenomas with suprasellar extension are often complicated by visual field defects, for which surgical decompression is the accepted treatment. However, surgical management of large prolactinomas is often not curative. This report describes a group of six unselected male patients who presented with visual field defects and reduced visual acuity due to large pituitary tumours with suprasellar extension. All six patients also had loss of libido and/or impotence. A rapid serum prolactin estimation enabled the diagnosis of prolactinoma to be made, and CT revealed a large pituitary adenoma with suprasellar extension. The patients were treated with bromocriptine, in doses increasing from 2.5 to 20 mg daily, as the sole therapy. Symptoms were relieved and serum prolactin levels were restored to normal or near normal; visual field defects resolved and visual acuity recovered in all patients. A repeat CT showed evidence of tumour shrinkage especially of the suprasellar extension, in all the patients. A diagnosis of prolactinoma should always be considered in a patient with a large pituitary tumour. The clinical history and a rapid prolactin assay will confirm the diagnosis. Treatment with bromocriptine leads to rapid improvement in perimetry and visual acuity as well as tumour shrinkage, obviating the need for pituitary surgery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8267889     DOI: 10.3109/02688699308995074

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  6 in total

1.  Combined treatment of invasive giant prolactinomas.

Authors:  Chonjiang Yu; Zhebao Wu; Jian Gong
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Detection of Visual Field Loss in Pituitary Disease: Peripheral Kinetic Versus Central Static.

Authors:  Fiona J Rowe; Christopher P Cheyne; Marta García-Fiñana; Carmel P Noonan; Claire Howard; Jayne Smith; Joanne Adeoye
Journal:  Neuroophthalmology       Date:  2015-05-13

3.  Pituitary Adenomas.

Authors:  Grant T. Liu
Journal:  Curr Treat Options Neurol       Date:  2002-07       Impact factor: 3.598

4.  Hyperprolactinemia and erectile dysfunction.

Authors:  S I Zeitlin; J Rajfer
Journal:  Rev Urol       Date:  2000

5.  Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.

Authors:  Latika Sibal; Paul Ugwu; Pat Kendall-Taylor; Steve G Ball; R Andy James; Simon H S Pearce; Keith Hall; Richard Quinton
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

6.  Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage.

Authors:  John R Lindsay; Janet A Harding; Peter K Ellis; Brian Sheridan; A Brew Atkinson
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.